The NCPE recommends that omaveloxolone not be considered for reimbursement

NCPE assessment completed, 16/12/2025. The National Centre for Pharmacoeconomics (NCPE) is a team of experts who look at the health benefits and costs of medicines. The HSE asks us to advise on whether or not a new medicine is good value for money. We give unbiased advice to help the HSE provide the most effective, safe and cost-effective (value for money) treatments for patients. 

After reviewing the data presented by the pharmaceutical company, we recommend that the HSE consider not providing omaveloxolone. This is because we are unsure based on the available clinical evidence that omaveloxolone leads to meaningful improvements in Friedreich’s ataxia symptoms. The current price of the medicine is too high, and there is no price at which omaveloxolone can be cost effective. We believe that the medicine is very poor value for money.